Hyperoxaluria Type

• FDA approval · 2025-04-04
  FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for OXLUMO (lumasiran) from Alnylam Pharmaceuticals, authorizing an updated approved product.

• FDA approval · 2023-09-19
  FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for OXLUMO (LUMASIRAN) submitted by Alnylam Pharmaceuticals.

• FDA approval · 2022-10-06
  FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for OXLUMO (lumasiran) submitted by Alnylam Pharmaceuticals, resulting in changes to the product…

• FDA approval · 2020-11-23
  FDA Approved: OXLUMO — Original Application (Alnylam Pharmaceuticals, Inc.)

  FDA approved OXLUMO (lumasiran) from Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1.

• EMA approval · 2020-10-16
  First treatment for rare condition primary hyperoxaluria type 1

  EMA announces the first treatment for the rare genetic disorder primary hyperoxaluria type 1.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.